Earlier this week, New York City-based Pfizer called off its proposed $150 billion takeover of Ireland-based Allergan, due in part to new regulations from the U.S. Department of the Treasury. Now Allergan CEO Brent Saunders has shared a few choice words about the Treasury in a recent interview with CNBC.
"For the rules to be changed after the game has started to be played is a bit un-American," Mr. Saunders said in the interview, according to the report.
On April 4, the U.S. Treasury Department issued regulations that would make tax inversions less lucrative for companies.
Mr. Saunders stressed that the deal seems to only have a direct effect on the Pfizer-Allergan deal. "I don't believe, based on an initial review, it impacts any other deal in virtually any other circumstance," he said, according to The Hill.
However, White House press secretary Josh Earnest claimed targeting the Pfizer-Allergan transaction was not the Treasury's aim, according to the report.